肝细胞癌的基因组不稳定性:生物标记物和在免疫疗法中的应用。

IF 3.7 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY
Jui-Hsiang Hung , Chiao-Feng Teng , Hsu-chin Hung , Yi-Lin Chen , Pin-Jun Chen , Chung-Liang Ho , Cheng-Hsiang Chuang , Wenya Huang
{"title":"肝细胞癌的基因组不稳定性:生物标记物和在免疫疗法中的应用。","authors":"Jui-Hsiang Hung ,&nbsp;Chiao-Feng Teng ,&nbsp;Hsu-chin Hung ,&nbsp;Yi-Lin Chen ,&nbsp;Pin-Jun Chen ,&nbsp;Chung-Liang Ho ,&nbsp;Cheng-Hsiang Chuang ,&nbsp;Wenya Huang","doi":"10.1016/j.aohep.2024.101546","DOIUrl":null,"url":null,"abstract":"<div><p>Hepatocellular carcinoma (HCC) is one of the deadliest cancers. For patients with advanced HCC, liver function decompensation often occurs, which leads to poor tolerance to chemotherapies and other aggressive treatments. Therefore, it remains critical to develop effective therapeutic strategies for HCC. Etiological factors for HCC are complex and multifaceted, including hepatitis virus infection, alcohol, drug abuse, chronic metabolic abnormalities, and others. Thus, HCC has been categorized as a “genomically unstable” cancer due to the typical manifestation of chromosome breakage and aneuploidy, and oxidative DNA damage. In recent years, immunotherapy has provided a new option for cancer treatments, and the degree of genomic instability positively correlates with immunotherapy efficacies. This article reviews the endogenous and exogenous causes that affect the genomic stability of liver cells; it also updates the current biomarkers and their detection methods for genomic instabilities and relevant applications in cancer immunotherapies. Including genomic instability biomarkers in consideration of cancer treatment options shall increase the patients’ well-being.</p></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"29 6","pages":"Article 101546"},"PeriodicalIF":3.7000,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1665268124003405/pdfft?md5=743982fdcb7f7d0d5fb3cc57442ec238&pid=1-s2.0-S1665268124003405-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Genomic instabilities in hepatocellular carcinoma: biomarkers and application in immunotherapies\",\"authors\":\"Jui-Hsiang Hung ,&nbsp;Chiao-Feng Teng ,&nbsp;Hsu-chin Hung ,&nbsp;Yi-Lin Chen ,&nbsp;Pin-Jun Chen ,&nbsp;Chung-Liang Ho ,&nbsp;Cheng-Hsiang Chuang ,&nbsp;Wenya Huang\",\"doi\":\"10.1016/j.aohep.2024.101546\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Hepatocellular carcinoma (HCC) is one of the deadliest cancers. For patients with advanced HCC, liver function decompensation often occurs, which leads to poor tolerance to chemotherapies and other aggressive treatments. Therefore, it remains critical to develop effective therapeutic strategies for HCC. Etiological factors for HCC are complex and multifaceted, including hepatitis virus infection, alcohol, drug abuse, chronic metabolic abnormalities, and others. Thus, HCC has been categorized as a “genomically unstable” cancer due to the typical manifestation of chromosome breakage and aneuploidy, and oxidative DNA damage. In recent years, immunotherapy has provided a new option for cancer treatments, and the degree of genomic instability positively correlates with immunotherapy efficacies. This article reviews the endogenous and exogenous causes that affect the genomic stability of liver cells; it also updates the current biomarkers and their detection methods for genomic instabilities and relevant applications in cancer immunotherapies. Including genomic instability biomarkers in consideration of cancer treatment options shall increase the patients’ well-being.</p></div>\",\"PeriodicalId\":7979,\"journal\":{\"name\":\"Annals of hepatology\",\"volume\":\"29 6\",\"pages\":\"Article 101546\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2024-08-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S1665268124003405/pdfft?md5=743982fdcb7f7d0d5fb3cc57442ec238&pid=1-s2.0-S1665268124003405-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of hepatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1665268124003405\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of hepatology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1665268124003405","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

肝细胞癌(HCC)是最致命的癌症之一。晚期肝细胞癌患者通常会出现肝功能失代偿,导致对化疗和其他积极治疗的耐受性差。因此,开发有效的 HCC 治疗策略仍然至关重要。HCC 的致病因素复杂多样,包括肝炎病毒感染、酒精、药物滥用、慢性代谢异常等。因此,HCC 被归类为 "基因组不稳定 "癌症,其典型表现为染色体断裂和非整倍体,以及 DNA 氧化损伤。近年来,免疫疗法为癌症治疗提供了新的选择,而基因组不稳定的程度与免疫疗法的疗效呈正相关。本文回顾了影响肝细胞基因组稳定性的内源性和外源性原因,并更新了目前基因组不稳定的生物标记物及其检测方法以及在癌症免疫疗法中的相关应用。将基因组不稳定性生物标志物纳入癌症治疗方案的考虑范围,将增加患者的福祉。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Genomic instabilities in hepatocellular carcinoma: biomarkers and application in immunotherapies

Hepatocellular carcinoma (HCC) is one of the deadliest cancers. For patients with advanced HCC, liver function decompensation often occurs, which leads to poor tolerance to chemotherapies and other aggressive treatments. Therefore, it remains critical to develop effective therapeutic strategies for HCC. Etiological factors for HCC are complex and multifaceted, including hepatitis virus infection, alcohol, drug abuse, chronic metabolic abnormalities, and others. Thus, HCC has been categorized as a “genomically unstable” cancer due to the typical manifestation of chromosome breakage and aneuploidy, and oxidative DNA damage. In recent years, immunotherapy has provided a new option for cancer treatments, and the degree of genomic instability positively correlates with immunotherapy efficacies. This article reviews the endogenous and exogenous causes that affect the genomic stability of liver cells; it also updates the current biomarkers and their detection methods for genomic instabilities and relevant applications in cancer immunotherapies. Including genomic instability biomarkers in consideration of cancer treatment options shall increase the patients’ well-being.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Annals of hepatology
Annals of hepatology 医学-胃肠肝病学
CiteScore
7.90
自引率
2.60%
发文量
183
审稿时长
4-8 weeks
期刊介绍: Annals of Hepatology publishes original research on the biology and diseases of the liver in both humans and experimental models. Contributions may be submitted as regular articles. The journal also publishes concise reviews of both basic and clinical topics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信